|
gptkbp:instanceOf
|
gptkb:drug
monoamine oxidase inhibitor
|
|
gptkbp:approvalYear
|
2005 (EU)
2006 (US)
|
|
gptkbp:ATCCode
|
gptkb:N04BD02
|
|
gptkbp:brand
|
gptkb:Azilect
|
|
gptkbp:CASNumber
|
136236-51-6
|
|
gptkbp:contraindication
|
severe liver impairment
concomitant use with other MAO inhibitors
concomitant use with pethidine
|
|
gptkbp:developer
|
gptkb:Teva_Pharmaceutical_Industries
|
|
gptkbp:eliminationHalfLife
|
3 hours
|
|
gptkbp:hasMolecularFormula
|
C12H13N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
rasagiline
|
|
gptkbp:IUPACName
|
gptkb:(R)-N-propargyl-1-indanamine
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible MAO-B inhibitor
|
|
gptkbp:metabolism
|
hepatic
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
88–94%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1201197
5293726
6918293
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:depression
headache
insomnia
dyskinesia
arthralgia
|
|
gptkbp:UNII
|
6M497J7C5T
|
|
gptkbp:usedFor
|
gptkb:Parkinson's_disease
|
|
gptkbp:bfsParent
|
gptkb:monoamine_oxidase_inhibitors
gptkb:MAO_inhibitors
|
|
gptkbp:bfsLayer
|
6
|